At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed Aug 12, 2026 at 06:30 ET
Bio-Techne reported Q4 FY2026 adjusted EPS of $0.52, a 2.1% beat vs $0.52 consensus, on revenue of $321.2M (1% reported growth, 3% organic). Full-year revenue was flat at $1.2B. The results are largely procedural given the pending $73/share acquisition by Merck KGaA, with the company no longer holding earnings calls. The modest adjusted EPS decline and flat revenue are secondary to the deal's trajectory and premium.
- Q4 FY2026 revenue $321.2M, +1% reported / +3% organic vs prior year
- Adjusted EPS $0.52 vs $0.53 a year ago, beating consensus of $0.52
- GAAP EPS $0.35 vs $(0.11) a year ago, driven by prior-year impairment
- Full-year FY2026 revenue flat at $1.2B; adjusted EPS $1.93 vs $1.92
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access